White Paper AGA: Functional Dyspepsia

Nimish B Vakil; Colin W Howden; Paul Moayyedi; Jan Tack

doi:10.1016/j.cgh.2017.05.013

White Paper AGA: Functional Dyspepsia

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1191-1194. doi: 10.1016/j.cgh.2017.05.013. Epub 2017 May 18.

Authors

Nimish B Vakil¹, Colin W Howden², Paul Moayyedi³, Jan Tack⁴

Affiliations

¹ University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: nvakil@wisc.edu.
² University of Tennessee Health Science Center, Memphis, Tennessee.
³ McMaster University, Hamilton, Ontario, Canada.
⁴ University of Leuven, Leuven, Belgium.

PMID: 28529164
DOI: 10.1016/j.cgh.2017.05.013

Abstract

Functional dyspepsia remains a major challenge for clinicians with no approved drugs available in the Western World. In October 2016, a meeting was held in Washington, DC, sponsored by the American Gastroenterological Association's Center for Diagnostics and Therapeutics, which included members of the Food and Drug Administration (FDA) and the pharmaceutical industry, experts in FD, and representatives of patient organizations. This white paper summarizes our current status, progress with a validated patient reported outcome instrument in functional dyspepsia, future directions and needs.

Keywords: Dyspepsia; Functional Dyspepsia; Patient-Reported Outcome.

Publication types

Congress

MeSH terms

Dyspepsia / diagnosis*
Dyspepsia / drug therapy*
Humans
Treatment Outcome